NASDAQ:TFFP

TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis

$3.02
+0.44 (+17.02%)
(As of 04/23/2024 ET)
Today's Range
$2.54
$3.14
50-Day Range
$2.58
$8.99
52-Week Range
$2.51
$21.25
Volume
62,771 shs
Average Volume
28,566 shs
Market Capitalization
$7.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.00

TFF Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,280.2% Upside
$72.00 Price Target
Short Interest
Healthy
3.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($7.28) to ($7.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.31 out of 5 stars

TFFP stock logo

About TFF Pharmaceuticals Stock (NASDAQ:TFFP)

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

TFFP Stock Price History

TFFP Stock News Headlines

He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
TFF Pharmaceuticals, Inc. (TFFP)
Tff Pharmaceuticals Inc (TFFP)
TFF Pharmaceuticals Inc Ordinary Shares
See More Headlines
Receive TFFP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TFF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/23/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TFFP
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.00
High Stock Price Target
$100.00
Low Stock Price Target
$44.00
Potential Upside/Downside
+2,316.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-21,240,000.00
Net Margins
-2,897.95%
Pretax Margin
-2,894.14%

Debt

Sales & Book Value

Annual Sales
$730,000.00
Book Value
$4.04 per share

Miscellaneous

Free Float
2,378,000
Market Cap
$7.51 million
Optionable
Optionable
Beta
1.29
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

TFFP Stock Analysis - Frequently Asked Questions

Should I buy or sell TFF Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TFFP shares.
View TFFP analyst ratings
or view top-rated stocks.

What is TFF Pharmaceuticals' stock price target for 2024?

1 analysts have issued 1 year target prices for TFF Pharmaceuticals' shares. Their TFFP share price targets range from $44.00 to $100.00. On average, they predict the company's stock price to reach $72.00 in the next year. This suggests a possible upside of 2,280.2% from the stock's current price.
View analysts price targets for TFFP
or view top-rated stocks among Wall Street analysts.

How have TFFP shares performed in 2024?

TFF Pharmaceuticals' stock was trading at $7.02 at the beginning of the year. Since then, TFFP stock has decreased by 56.9% and is now trading at $3.0250.
View the best growth stocks for 2024 here
.

Are investors shorting TFF Pharmaceuticals?

TFF Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 86,600 shares, an increase of 86.6% from the March 15th total of 46,400 shares. Based on an average daily trading volume, of 28,500 shares, the days-to-cover ratio is currently 3.0 days. Approximately 3.4% of the shares of the company are short sold.
View TFF Pharmaceuticals' Short Interest
.

When is TFF Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TFFP earnings forecast
.

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) released its quarterly earnings results on Thursday, March, 28th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.00) by $0.01. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.20 million. TFF Pharmaceuticals had a negative trailing twelve-month return on equity of 163.14% and a negative net margin of 2,897.95%.

When did TFF Pharmaceuticals' stock split?

Shares of TFF Pharmaceuticals reverse split on the morning of Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Chimerix (CMRX) and DURECT (DRRX).

When did TFF Pharmaceuticals IPO?

TFF Pharmaceuticals (TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at a price of $5.00 per share. National Securities served as the underwriter for the IPO.

Who are TFF Pharmaceuticals' major shareholders?

TFF Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Westside Investment Management Inc. (1.56%). Insiders that own company stock include Aaron GL Fletcher, Carlson Capital L P, Glenn R Mattes, Harlan F Weisman, Kirk Allen Coleman, Malcolm Fairbairn, Randy H Thurman, Stephen Rocamboli and Zamaneh Mikhak.
View institutional ownership trends
.

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TFFP) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners